February 3, 2026
Paris, France – January 30, 2026 — Rapalogix Health announced today that it has been awarded First Place, Start-Up of the Year at the prestigious IMCAS Innovation Tank 2026, held during the IMCAS World Congress in Paris. The Congress drew nearly 22,000 global delegates and showcased groundbreaking treatments and state-of-the-art technologies shaping the future of medical aesthetics.
The IMCAS Innovation Tank is one of the most competitive global showcases for emerging technologies in dermatology, plastic surgery, and aging science. The 2026 session featured 12 international finalists, selected to present breakthrough solutions ranging from regenerative injectables to robotic- and AI-enabled medical systems. Rapalogix Health’s winning presentation highlighted RLX-201, a first-in-class pro-longevity fibroblast technology designed to restore youthful cellular function by modulating mTORC1 activity in the skin.
RLX-201, and Re-Q Pro-Longevity Serum containing RLX-201, distinguished themselves through advanced mechanistic science, strong translational potential, clinical relevance across both aesthetics and dermatology, and well-defined commercialization and growth plans.
“We are honored to be recognized on one of the world’s most influential stages for aesthetic and regenerative innovation,” said Rahul Mehta, PhD, CEO of Rapalogix Health. “RLX‑201 and Re-Q Pro-Longevity Serum represent a new category of skin longevity technology, grounded in mTOR‑targeted biology and built to elevate both patient outcomes and physician confidence. Winning at IMCAS validates the science and the promise behind our platform.”
As the Innovation Tank 2026 First Place winner, Rapalogix Health will continue advancing RLX-201 through clinical development and commercialization, while expanding collaborations with physicians and scientific partners globally.
About Rapalogix Health
Rapalogix Health is a New York-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products. Re-Q Pro-longevity Face Serum, the first product from Rapalogix’s professional skincare brand, Re-Q Health, is now available at select dermatology practices in the United States. Re-Q Pro-Longevity Face Serum is powered by RLX-201, Rapalogix’s proprietary pro-longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime.
For more information on Rapalogix Health, visit www.rapalogix.com or follow Rapalogix on LinkedIn and Instagram.
For more information on Re-Q Health, visit www.reqhealth.com or follow Re-Q Health on Instagram.
About IMCAS
IMCAS congresses are medical research conferences focused on providing physicians (plastic surgeons, dermatologists and medical aesthetic practitioners) with the latest academic updates for their professional progress in the plastic surgery, dermatology and aging science fields. IMCAS brings together the latest evidence-based techniques from prominent speakers and the newest developments from the major industry players. Learn more at https://www.imcas.com/en/about.
